VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
BMRABiomerica, Inc.
$1.75$5M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksBMRACash Flow

Biomerica, Inc. (BMRA) Cash Flow Statement

30Y historyFree accessUpdated daily

Free cash flow remains deeply negative at -$1.3 million in 2026Q3, highlighting an unsustainable burn rate that lacks support from operational efficiencies.

BMRA Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMMay'25May'24May'23May'22May'21May'20May'19May'18May'17May'16May'15May'14May'13May'12May'11May'10May'09May'08May'07May'06May'05May'04May'03May'02May'01May'00May'99May'98May'97May'96
Cash from Operations-3.17M-3.84M-5.36M-5.47M-480.53K-5.25M-4.3M-2.24M-1.17M-722.86K-208.78K-405.48K-862.27K1.39M147.41K328.8K-236.98K-102K-194.59K463.71K-385.17K72.92K-75.03K512.54K-131.07K108.95K-2.56M-400K400K700K500K
Operating CF Margin %--72.32%-99%-102.53%-2.55%-72.95%-64.21%-43.15%-21.1%-12.48%-4.06%-8.17%-16.84%21.54%2.42%6.71%-4.67%-2.07%-3.95%8.07%-5.36%0.79%-0.82%5.66%-1.52%1.22%-31.91%-4.6%4.26%7.61%5.26%
Operating CF Growth %71.84%28.35%2.06%-1039.15%90.85%-22.2%-91.51%-91.11%-62.44%-246.23%48.51%52.98%-161.85%845.67%-55.17%238.75%-132.33%47.58%-141.97%220.39%-628.21%197.19%-114.64%491.03%-220.3%104.25%-540.95%-200%-42.86%40%0%
Net Income-3.94M-4.97M-5.98M-7.14M-4.53M-7.45M-2.34M-2.39M-1.47M-908.56K-1.5M-331.41K-215.66K536.96K548.43K157.45K-331.45K354.18K1.71M509.01K153.76K-21.46K-299.05K-223.87K-566.67K-578.89K-3.89M-100K100K400K400K
Depreciation & Amortization414K400K374K351K594.82K375.86K398.63K162.91K186.6K219.22K232.42K253.28K207.03K216.71K180.12K147.81K114.01K88.65K65.83K56.74K122.05K159.32K144.16K116.55K192.42K208.99K222.32K300K200K200K300K
Stock-Based Compensation493K460K837K1.19M1.26M1.35M200.47K151.22K18.47K21.73K15.15K10.02K11K20.86K53.62K27.97K000000000000000
Deferred Taxes000000010K31K-16.5K703K-298K-217K9K-569.08K21.15K000000000000000
Other Non-Cash Items-20K4K31K168K-719.15K1.55M-37.97K12.91K23.4K8.07K-923-39.29K-50.59K-1.19K541.93K-72.37K-37.28K215.7K-1.12M145.82K-230.44K-178.04K163K241.96K318.02K362.72K639.87K-100K200K-100K200K
Working Capital Changes117K268K-625K-38K2.91M-1.09M-2.54M-188.02K32.14K-46.81K341.35K-69-597.06K611.69K-607.62K46.8K17.75K-760.53K-853.09K-247.86K-430.54K113.1K-83.14K377.89K-74.84K116.13K464.85K-500K-100K100K-400K
Change in Receivables315K209K-215K-291K1.37M-455.61K-309.09K-670.13K252.5K-132.26K151.16K348.67K-490.32K326.32K-534.43K261.77K-313.95K-28.56K0000000000000
Change in Inventory34K882K-115K534K1.56M-1.91M-717.46K21.39K-457.27K150.47K137.13K-243.38K-158.96K245.96K-27.71K3.81K292.65K-370.19K-302.49K-333.68K-261.86K32.33K-17.91K261.08K-91.51K-128.3K198.41K-500K-100K-400K-200K
Change in Payables98K-466K246K-80K-403.33K-403.33K-12.88K343.99K319.17K10.45K-30.58K-29.14K103.56K-5.45K-63.6K-121.76K53.23K-293.2K0000000000000
Cash from Investing-15K-37K-115K-78K-170.34K-295.58K-118.93K-171.11K-130.35K-96.08K-95.19K-22.78K-282.53K-257.12K-113.17K-431.68K-269.4K-215.89K1.52M-62.7K-251.74K-233.35K-390.12K-236.28K219.45K50.53K-360.49K00-400K-100K
Capital Expenditures4K-37K-51K-78K-170.34K-295.58K-118.93K-171.11K-130.35K-96.08K-95.19K-24.68K-283.73K-257.12K-214.8K-266.36K-369.4K-115.89K-264.78K-112.69K-252.43K-242.24K-436.09K-236.28K-11.73K-61.92K-206.38K-100K-100K-200K-100K
CapEx % of Revenue0.09%0.7%0.94%1.46%0.9%4.11%1.78%3.29%2.34%1.66%1.85%0.5%5.54%3.97%3.53%5.44%7.28%2.35%5.37%1.96%3.51%2.61%4.76%2.61%0.14%0.69%2.57%1.15%1.06%2.17%1.05%
Acquisitions0000000000000000000000000000000
Investments-------------------------------
Other Investing-19K0-64K00000000000101.63K000000000192.06K26.79K-172.29K-200K-100K00
Cash from Financing1.46M2.11M-81K9.39M2.39M1.11M12.37M1.91M1.29M157.73K1.11M9.56K185.28K258.51K55.4K37.89K-32.45K-106.94K184.38K-4.03K538.95K159.94K292.36K-77.36K114.05K-638.25K1.89M200K-300K800K-500K
Debt Issued (Net)0000000000000-43K7.61K-45.11K-42.28K-140.33K35.87K-35.12K-1.5K158.77K3.34K-126.69K205.67K75K-20K100K-300K-300K-500K
Equity Issued (Net)1.54M2.14M-81K9.31M2.32M1.01M12.15M1.78M1.27M0995.98K0150K250K000-3K148.51K31.09K503.19K1.17K322.5K40K11.33K248.98K2.03M200K01.1M0
Dividends Paid0000000000000000000000000000000
Share Repurchases-19K00-705K-85K-165.92K00000000000-3K0000000000000
Other Financing-87K-32K081K77.52K102.25K223.53K130.85K27.44K0109.94K035.27K51.51K00036.39K0037.25K0-33.48K9.33K-102.94K-962.23K-117.91K-100K000
Net Change in Cash-1.72M-1.77M-5.55M3.8M1.72M-4.44M7.95M-518.12K-20.56K-663.46K800.62K-420.82K-960.67K1.39M88.07K-65.94K-540.62K-426.56K1.51M396.99K-97.96K-493-172.79K198.89K202.43K-478.76K-1.03M-100K100K1.1M-100K
Free Cash Flow-3.8M-3.88M-5.48M-5.55M-650.87K-5.55M-4.42M-2.42M-1.3M-818.94K-303.97K-430.16K-1.15M1.14M-67.39K62.44K-606.38K-217.89K-459.38K351.01K-637.6K-169.32K-511.12K276.25K-142.8K47.04K-2.77M-500K300K500K400K
FCF Margin %-83.17%-73.02%-101.13%-103.99%-3.45%-77.06%-65.99%-46.44%-23.45%-14.14%-5.91%-8.67%-22.38%17.56%-1.11%1.27%-11.95%-4.42%-9.32%6.11%-8.87%-1.83%-5.57%3.05%-1.66%0.53%-34.48%-5.75%3.19%5.43%4.21%
FCF Growth %1.27%29.18%1.37%-753.01%88.27%-25.61%-82.86%-85.13%-59.3%-169.41%29.34%62.46%-200.8%1787.17%-207.91%110.3%-178.3%52.57%-230.87%155.05%-276.56%66.87%-285.02%293.45%-403.6%101.7%-454.04%-266.67%-40%25%33.33%
FCF per Share-1.26-1.69-0.33-0.39-0.05-0.47-0.43-0.26-0.15-0.10-0.04-0.06-0.160.15-0.010.01-0.09-0.03-0.070.05-0.10-0.03-0.090.05-0.030.01-0.61-0.130.080.130.11
FCF Conversion (FCF/Net Income)0.96x0.77x0.90x0.77x0.11x0.71x1.84x0.94x0.80x0.80x0.14x1.22x4.00x2.60x0.27x2.09x0.71x-0.29x-0.11x0.86x-1.67x0.45x0.34x-2.29x0.31x-0.04x0.66x4.00x4.00x1.75x1.25x
Interest Paid00000367947372821671380000000000000000000
Taxes Paid27K10K41K51K24K27.17K7.39K14.24K800800-800-8000000000000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Capital exhaustion and liquidity

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Persistent Disconnect Between Earnings Cash

According to recent financial disclosures, Biomerica's operating cash flow consistently tracks net losses, with an OCF/NI ratio of 0.95 in 2026Q3, indicating that the company lacks the non-cash accruals or operational efficiencies necessary to bridge the widening gap between accounting losses and actual cash outflows.

The tight correlation between net income and operating cash flow suggests that the company's losses are largely cash-based rather than driven by non-cash accounting charges. This implies that the business is consuming liquidity at a rate nearly identical to its reported net losses, leaving little room for operational error.

Negative Free Cash Flow Trajectory

As reported in quarterly filings, the company's free cash flow remains deeply negative, reaching -$1.3M in 2026Q3, which reflects a deteriorating trend where the firm is unable to generate positive cash flow from its core operations to offset even minimal capital expenditure requirements.

The consistent negative FCF margin, which hit -130.4% in the most recent quarter, underscores the structural inability of the current business model to self-fund. Investors should monitor whether this burn rate accelerates as the company attempts to scale the InFoods platform without a stable revenue base.

Volatile Working Capital Management Cycles

Based on the provided cash flow statements, working capital changes have been highly erratic, swinging from a $629.0K inflow in 2025Q4 to an $83.0K outflow in 2026Q3, suggesting that the company lacks a predictable cycle for managing its inventory and accounts receivable during this transition.

This volatility may indicate inconsistent collection patterns or erratic inventory stocking orders that do not align with steady end-user demand. Such fluctuations complicate cash flow forecasting and suggest that the company's liquidity position is highly sensitive to the timing of individual customer payments.

SBC Masking True Cash Burn

As evidenced by the quarterly data, stock-based compensation remains a recurring adjustment, with $135.0K recorded in 2026Q3, which effectively masks the true extent of the company's cash-based operating losses by shifting compensation costs away from the cash flow statement and into equity dilution.

While SBC is a non-cash expense, its consistent presence suggests that the company is relying on equity-based incentives to preserve its limited cash reserves. This practice warrants further investigation, as it may indicate that the firm is prioritizing talent retention over the preservation of shareholder value during a period of significant financial distress.

BMRA — Frequently Asked Questions

Quick answers to the most common questions about buying BMRA stock.

How much cash does Biomerica, Inc. (BMRA) generate from operations?

Biomerica, Inc. (BMRA) generated $-3.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Biomerica, Inc.'s free cash flow?

Biomerica, Inc. (BMRA) reported negative free cash flow of $3.9M in 2025, indicating capital requirements exceeded cash from operations.

What is Biomerica, Inc.'s capital expenditure (CapEx)?

Biomerica, Inc. (BMRA) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.